Scinopharm Taiwan Ltd, based in Taiwan, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for A leading process R&D and API Manufacturing service provider to the Global Pharmaceutical Industry.
One of their notable products is CELECOXIB USP, with a corresponding US DMF Number 30926.
Remarkably, this DMF maintains an Active status since its submission on October 27, 2016, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 22, 2017, and payment made on September 22, 2016, indicating their dedication to facilitating drug approvals, Categorized as Type II